Neoplasm of thorax

Summary

Neoplasm of thorax (MONDO:0021350) is a cancer (an umbrella term covering 11 Mondo subtypes) and 78 clinical trials. Top therapeutic interventions include pemetrexed, pralsetinib, and alectinib. A subtype of neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 11 Mondo subtypes
• Clinical trials: 78

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neoplasm of thorax
Mondo ID	MONDO:0021350
ICD-10-CM	C30-C39
NCIT	C3406
SNOMED CT	255058005
UMLS	C0039981
MedGen	11793
Anatomy (UBERON)	UBERON:0000915
Is cancer (heuristic)	yes

Also known as: neoplasm of the thorax · neoplasm of thoracic segment of trunk · thoracic neoplasm · thoracic segment of trunk neoplasm · thoracic segment of trunk neoplasm (disease) · thoracic segment of trunk tumor · thoracic segment of trunk tumour · thoracic tumor · thoracic tumour · tumor of the thorax · tumor of thoracic segment of trunk · tumor of thorax · tumour of the thorax · tumour of thoracic segment of trunk · tumour of thorax

Disease family

This is a subtype of neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › neoplasm of thorax

Related subtypes (47): pre-malignant neoplasm, endocrine gland neoplasm, giant cell tumor, hematopoietic and lymphoid system neoplasm, skin neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, peritoneal neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer

Subtypes (11): thoracic benign neoplasm, thoracic cancer, breast neoplasm, lung neoplasm, heart neoplasm, neoplasm of pericardium, neoplasm of mediastinum, neoplasm of chest wall, neoplasm of aortic body, sternal neoplasm, axillary neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 78.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	47
PHASE2	10
PHASE1	8
PHASE3	7
PHASE1/PHASE2	3
PHASE4	1
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05521789	PHASE4	RECRUITING	Erector Spinae Block for Thoracic Surgery
NCT00880971	PHASE3	COMPLETED	Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer
NCT01024413	PHASE3	COMPLETED	Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
NCT03134872	PHASE3	COMPLETED	A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
NCT03331588	PHASE3	COMPLETED	Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
NCT03402048	PHASE3	UNKNOWN	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
NCT03521986	PHASE3	UNKNOWN	Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS
NCT04209868	PHASE2/PHASE3	UNKNOWN	Preoperative Paravertebral Block in Cancer Surgery of the Lung
NCT04222972	PHASE3	TERMINATED	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04776447	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
NCT06177925	PHASE2	RECRUITING	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
NCT06758700	PHASE2	RECRUITING	Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
NCT06917573	PHASE2	RECRUITING	PALACE: Cemiplimab Trial According to ctDNA Levels
NCT07205536	PHASE2	RECRUITING	Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
NCT07242547	PHASE2	RECRUITING	Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT03037385	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03389256	PHASE2	UNKNOWN	Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
NCT04133337	PHASE1/PHASE2	UNKNOWN	Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
NCT04371796	PHASE2	UNKNOWN	Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
NCT04644315	PHASE2	TERMINATED	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
NCT04725448	PHASE2	UNKNOWN	Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
NCT04841538	PHASE1/PHASE2	WITHDRAWN	A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
NCT06333951	PHASE1	ACTIVE_NOT_RECRUITING	Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT00437372	PHASE1	COMPLETED	Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
NCT02111824	PHASE1	TERMINATED	A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
NCT02587455	PHASE1	COMPLETED	Pembrolizumab and Palliative Radiotherapy in Lung
NCT02897778	PHASE1	COMPLETED	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02909452	PHASE1	COMPLETED	Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT04862780	PHASE1	TERMINATED	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT05153408	PHASE1	TERMINATED	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT03477162	EARLY_PHASE1	TERMINATED	Metformin Pharmacology in Human Cancers: A Proof of Principle Study
NCT02941458	Not specified	RECRUITING	Thoracic Tumours Register
NCT05053230	Not specified	RECRUITING	A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
NCT05189054	Not specified	RECRUITING	Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
NCT06004440	Not specified	ACTIVE_NOT_RECRUITING	Real World Registry for Use of the Ion Endoluminal System
NCT06104774	Not specified	RECRUITING	The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery
NCT06185062	Not specified	RECRUITING	Pelvic Cancer Registry for Online Adapted Radiotherapy
NCT06376084	Not specified	ACTIVE_NOT_RECRUITING	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06494241	Not specified	ACTIVE_NOT_RECRUITING	Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
NCT06840288	Not specified	RECRUITING	Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMETREXED	4	3
PRALSETINIB	4	2
ALECTINIB	4	1
ERLOTINIB	4	1
GEFITINIB	4	1
SOTORASIB	4	1
TARLATAMAB	4	1
TENIPOSIDE	4	1
VINORELBINE	4	1
CAMRELIZUMAB	3	2
ENTINOSTAT	3	2
ADEBRELIMAB	3	1
SINTILIMAB	3	1
MECAPEGFILGRASTIM	2	1
TALETRECTINIB	2	1
TIGOZERTINIB	2	1
CHEMBL4297597	0	2
CHEMBL5174767	0	1
CHEMBL6175025	0	1
CHEMBL454299	0	1